When the current patient cohort was grouped into low-grade cancers and high-grade cancers based on pathological Gleason score, we found that Wnt5a protein expression was significantly associated with better outcome in PCa patients with low-grade cancers as patients in this group with high-Wnt5a protein expression had significantly longer BCR-free time after RP compared to patients with low-Wnt5a expression. The gene discussed is BCR; the disease is cancer.